Revvity EBITDA Margin 2010-2024 | RVTY
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Revvity (RVTY) over the last 10 years. The current EBITDA margin for Revvity as of September 30, 2024 is .
| Revvity EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-06-30 | $2.71B | $0.71B | 26.28% |
| 2024-03-31 | $2.73B | $0.71B | 25.90% |
| 2023-12-31 | $2.75B | $0.74B | 26.86% |
| 2023-09-30 | $2.80B | $0.80B | 28.54% |
| 2023-06-30 | $2.84B | $0.85B | 29.89% |
| 2023-03-31 | $3.02B | $1.02B | 33.70% |
| 2022-12-31 | $3.31B | $1.22B | 36.90% |
| 2022-09-30 | $3.00B | $1.38B | 45.92% |
| 2022-06-30 | $3.15B | $1.41B | 44.67% |
| 2022-03-31 | $3.48B | $1.46B | 41.87% |
| 2021-12-31 | $3.83B | $1.61B | 42.07% |
| 2021-09-30 | $3.63B | $1.63B | 44.88% |
| 2021-06-30 | $3.74B | $1.68B | 45.09% |
| 2021-03-31 | $3.32B | $1.51B | 45.47% |
| 2020-12-31 | $2.66B | $1.07B | 40.33% |
| 2020-09-30 | $3.23B | $0.86B | 26.60% |
| 2020-06-30 | $2.98B | $0.69B | 23.15% |
| 2020-03-31 | $2.89B | $0.60B | 20.92% |
| 2019-12-31 | $2.88B | $0.60B | 20.87% |
| 2019-09-30 | $2.84B | $0.56B | 19.82% |
| 2019-06-30 | $2.80B | $0.55B | 19.52% |
| 2019-03-31 | $2.78B | $0.54B | 19.34% |
| 2018-12-31 | $2.78B | $0.53B | 18.98% |
| 2018-09-30 | $2.66B | $0.49B | 18.33% |
| 2018-06-30 | $2.54B | $0.47B | 18.36% |
| 2018-03-31 | $2.39B | $0.43B | 17.89% |
| 2017-12-31 | $2.26B | $0.41B | 18.17% |
| 2017-09-30 | $2.18B | $0.40B | 18.42% |
| 2017-06-30 | $2.14B | $0.40B | 18.58% |
| 2017-03-31 | $2.13B | $0.39B | 18.21% |
| 2016-12-31 | $2.12B | $0.40B | 18.77% |
| 2016-09-30 | $2.00B | $0.35B | 17.56% |
| 2016-06-30 | $2.05B | $0.35B | 17.29% |
| 2016-03-31 | $2.08B | $0.36B | 17.34% |
| 2015-12-31 | $2.11B | $0.37B | 17.34% |
| 2015-09-30 | $2.10B | $0.30B | 14.51% |
| 2015-06-30 | $2.07B | $0.29B | 13.89% |
| 2015-03-31 | $2.07B | $0.29B | 13.99% |
| 2014-12-31 | $2.07B | $0.28B | 13.48% |
| 2014-09-30 | $2.22B | $0.40B | 17.90% |
| 2014-06-30 | $2.20B | $0.40B | 18.24% |
| 2014-03-31 | $2.18B | $0.38B | 17.18% |
| 2013-12-31 | $2.16B | $0.36B | 16.74% |
| 2013-09-30 | $2.13B | $0.24B | 11.12% |
| 2013-06-30 | $2.12B | $0.22B | 10.38% |
| 2013-03-31 | $2.10B | $0.23B | 10.95% |
| 2012-12-31 | $2.11B | $0.24B | 11.25% |
| 2012-09-30 | $2.08B | $0.25B | 11.82% |
| 2012-06-30 | $2.03B | $0.24B | 11.65% |
| 2012-03-31 | $1.98B | $0.22B | 11.10% |
| 2011-12-31 | $1.92B | $0.21B | 11.05% |
| 2011-09-30 | $1.85B | $0.27B | 14.84% |
| 2011-06-30 | $1.81B | $0.27B | 15.12% |
| 2011-03-31 | $1.76B | $0.26B | 15.04% |
| 2010-12-31 | $1.70B | $0.25B | 14.63% |
| 2010-09-30 | $1.54B | $0.23B | 14.85% |
| 2010-06-30 | $1.49B | $0.20B | 13.33% |
| 2010-03-31 | $1.51B | $0.20B | 13.45% |
| 2009-12-31 | $1.55B | $0.20B | 12.90% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $15.535B | $2.751B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $96.890B | 12.02 |
| Cencora (COR) | United States | $46.107B | 17.62 |
| DiDi Global (DIDIY) | China | $23.233B | 0.00 |
| ICON (ICLR) | Ireland | $18.679B | 16.64 |
| Avantor (AVTR) | United States | $15.498B | 23.24 |
| Natera (NTRA) | United States | $15.385B | 0.00 |
| Viatris (VTRS) | United States | $13.858B | 4.22 |
| BioMerieux (BMXMF) | France | $13.601B | 0.00 |
| Solventum (SOLV) | United States | $12.636B | 0.00 |
| CochLear (CHEOY) | Australia | $12.565B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.202B | 28.74 |
| Charles River Laboratories (CRL) | United States | $9.742B | 18.41 |
| Sonic Healthcare (SKHHY) | Australia | $8.273B | 0.00 |
| HealthEquity (HQY) | United States | $7.792B | 42.29 |
| Doximity (DOCS) | United States | $7.787B | 49.34 |
| Bausch + Lomb (BLCO) | Canada | $6.975B | 32.47 |
| Life Times (LTH) | United States | $4.762B | 31.52 |
| PACS (PACS) | United States | $4.502B | 0.00 |
| Sotera Health (SHC) | United States | $4.367B | 23.36 |
| Organon (OGN) | United States | $4.239B | 4.28 |
| Surgery Partners (SGRY) | United States | $3.778B | 41.86 |
| BrightSpring Health Services (BTSG) | United States | $3.070B | 65.30 |
| Ardent Health Partners (ARDT) | United States | $2.577B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.546B | 0.00 |
| Concentras Parent (CON) | United States | $2.480B | 0.00 |
| Premier (PINC) | United States | $2.271B | 11.34 |
| GoodRx Holdings (GDRX) | United States | $2.254B | 84.86 |
| GeneDx Holdings (WGS) | United States | $2.057B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.575B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.507B | 7.57 |
| Progyny (PGNY) | United States | $1.425B | 25.06 |
| Establishment Labs Holdings (ESTA) | $1.338B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.319B | 12.91 |
| CareDx (CDNA) | United States | $1.228B | 0.00 |
| Agilon Health (AGL) | United States | $1.123B | 0.00 |
| Embecta (EMBC) | United States | $0.864B | 5.76 |
| InnovAge Holding (INNV) | United States | $0.822B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| SBC Medicals (SBC) | United States | $0.722B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.488B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.483B | 0.00 |
| Enhabit (EHAB) | United States | $0.382B | 33.04 |
| DocGo (DCGO) | United States | $0.355B | 13.35 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.309B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.255B | 0.00 |
| ModivCare (MODV) | United States | $0.232B | 7.37 |
| Beauty Health (SKIN) | United States | $0.211B | 0.00 |
| Biodesix (BDSX) | United States | $0.195B | 0.00 |
| LifeMD (LFMD) | United States | $0.192B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.178B | 0.00 |
| MultiPlan (MPLN) | United States | $0.136B | 0.00 |
| Nutex Health (NUTX) | United States | $0.127B | 0.00 |
| So-Young (SY) | China | $0.092B | 22.35 |
| Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.059B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.057B | 0.00 |
| OncoCyte (OCX) | United States | $0.049B | 0.00 |
| NeueHealth (NEUE) | United States | $0.041B | 1.63 |
| Co-Diagnostics (CODX) | United States | $0.039B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.036B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| Oncology Institute (TOI) | United States | $0.021B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |